MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.

Anticancer Research 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28314308″>Link] Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, Pinelli V, Morabito A, Fedeli F, Pistillo MP5, Roncella S Abstract BACKGROUND: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). […]

Comments Off on Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.

Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma

International Journal of Biological Markers 2017 March [Link] Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a relatively rare tumor, with the epithelioid type occurring more frequently. Several biomarkers have […]

Comments Off on Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma

The Immune Microenvironment, Genome -Wide Copy Number Aberrations and Survival in Mesothelioma

Journal of Thoracic Oncology 2017 February [Epub ahead of print] [Link] Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T Abstract INTRODUCTION: Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) […]

Comments Off on The Immune Microenvironment, Genome -Wide Copy Number Aberrations and Survival in Mesothelioma

Anti-CTLA-4 therapy for malignant mesothelioma

Immunotherapy 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28231719″>Link] Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L Abstract Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims […]

Comments Off on Anti-CTLA-4 therapy for malignant mesothelioma

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

Lung Cancer (Netherlands) 2017 Februray [Epub 2016 December 23] [Link] Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K Abstract OBJECTIVES: Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial hyperplasia (RMH) is still challenging. Detection of homozygous deletion (HD) of 9p21 region […]

Comments Off on Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

3-(2-deoxy-β-D-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers

Toxicology Letters 2017 February 7 [Epub ahead of print] [Link] Bonassi S, Cellai F, Munnia A, Ugolini D, Cristaudo A, Neri M, Milić M, Bonotti A, Giese RW, Peluso ME Abstract Asbestos is the commercial name for a group of silicate minerals naturally occurring in the environment and widely used in the industry. Asbestos exposure […]

Comments Off on 3-(2-deoxy-β-D-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

British Journal of Cancer 2017 February 7 [Epub ahead of print] [Link] Arnold DT, De Fonseka D, Hamilton FW, Rahman NM3, Maskell NA Abstract BACKGROUND: Radiological markers of treatment response and prognostication in malignant pleural mesothelioma have limitations due to the morphology of the disease. Serum or pleural fluid biomarkers that could act as an […]

Comments Off on Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

Cancer Science 2017 February 9 [Epub ahead of print] [Link] Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii GI, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S Abstract Malignant pleural mesothelioma (MPM) is characterized by dissemination and aggressive growth in the thoracic cavity. Podoplanin (PDPN) is […]

Comments Off on Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

Modern Pathology 2017 January 27 [Epub ahead of print] [Link] Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y Abstract Sarcomatoid mesothelioma, a histological subtype of malignant pleural mesothelioma, is a very aggressive tumor with a poor prognosis. Histological diagnosis of sarcomatoid mesothelioma largely depends on the histomorphological […]

Comments Off on MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Oncotarget 2017 January 18 [Epub ahead of print] [Link] Pei D1, Li Y, Liu X, Yan S, Guo X, Xu X, Guo X Abstract Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. […]

Comments Off on Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis